【AI生物科技新星Nucleai获1400万美元B+轮融资，引领病理图像分析新纪元】
AI驱动的空间生物标志物分析初创公司Nucleai近日传来喜讯，成功完成了1400万美元的B+轮融资，引领了医疗科技领域的又一轮创新热潮。本轮融资由知名投资机构M Ventures领投，Section 32、Sanofi Ventures、Debiopharm、复星锐正资本、Vertex Ventures Israel以及Grove Ventures等一众行业重量级投资者纷纷参与其中，彰显了市场对Nucleai技术潜力的高度认可。
Nucleai专注于利用人工智能和机器学习技术，对细胞和组织层面的病理图像及空间数据进行深度分析，以预测疾病的治疗效果。这一创新方法有望打破传统病理学的局限，为精准医疗提供更高效、更精准的决策支持。
本次融资将助力Nucleai进一步研发其AI平台，加速在病理学和临床试验中的应用，旨在为患者提供更加个性化的治疗方案。Nucleai的先进技术不仅能够提升疾病诊断的准确性，还可能在药物研发领域开辟新的可能，对整个医疗行业产生深远影响。
Nucleai的创始人及首席执行官表示，公司将持续投入研发，以人工智能的力量推动生物医学研究的边界。这一轮融资的注入，无疑将加速Nucleai实现其愿景，即利用AI技术改变我们理解和治疗疾病的方式。
来源：CTech
英语如下：
News Title: “AI Biotech Rising Star Nucleai Secures $14M B+ Round, Pioneering a Revolution in Pathological Analysis”
Keywords: AI bioanalytics, Nucleai funding, pathological image recognition
News Content: 【AI Biotech Trailblazer Nucleai Bags $14 Million B+ Funding, Launching a New Era in Pathological Image Analysis】
Nucleai, a pioneering startup in AI-driven spatial biomarker analysis, has announced a successful $14 million B+ funding round, igniting another wave of innovation in the healthcare tech sector. The round was led by renowned investor M Ventures, with participation from Section 32, Sanofi Ventures, Debiopharm, Fosun RZ Capital, Vertex Ventures Israel, and Grove Ventures, indicating high market confidence in Nucleai’s technological potential.
Specializing in AI and machine learning-based deep analysis of cellular and tissue-level病理图像 and spatial data, Nucleai aims to predict disease treatment outcomes. This innovative approach promises to break the confines of traditional pathology, offering more efficient and precise decision-making support for precision medicine.
The fresh funding will fuel the further development of Nucleai’s AI platform, accelerating its application in pathology and clinical trials. The goal is to tailor more personalized treatment options for patients. Not only does Nucleai’s advanced technology enhance diagnostic accuracy, but it also opens new possibilities in drug discovery, significantly impacting the entire healthcare industry.
The company’s founder and CEO expressed commitment to ongoing R&D, leveraging AI to push the boundaries of biomedical research. This funding injection will undoubtedly hasten Nucleai’s pursuit of its vision – transforming the way we understand and treat diseases through AI technology.
Source: CTech
【来源】https://www.calcalistech.com/ctechnews/article/r11brac1a
Views: 1